CYP2C19 genotype-directed P(2)Y(12) inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention

OBJECTIVE: To study the use of CYP2C19 genotyping to guide P2Y(12) inhibitor selection to maximize efficacy, and attenuate risk in appropriate patients who underwent PCI for CAD. METHODS: We performed a retrospective analysis of 868 patients with CAD who received CYP2C19 genotyping after PCI and cha...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Indian Heart J
Hlavní autoři: Stys, Tomasz P., Gedela, Maheedhar, Gowda, Smitha N., Bares, Valerie, Fanta, Lauren, Petrasko, Marian, Hajek, Catherine, Larson, Eric, Stys, Adam T.
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8322803/
https://ncbi.nlm.nih.gov/pubmed/34154743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ihj.2021.03.004
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky